Information from Industry - Sponsored Supplement
A Second-line Option for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer (DTC)
Developed under the direction and sponsorship of Exelixis, Inc. This content was peer reviewed by Federal Practitioner.
July 15, 2024|Federal Practitioner
In this special supplement to Federal Practitioner, Dr. Jameel Muzaffar, MD shares insights into a second-line treatment option for previously treated radioiodine-refractory differentiated thyroid cancer (DTC), along with an exploratory analysis of BRAF mutation status. It discusses the challenges associated with metastatic DTC and the significance of understanding factors like BRAF mutation status in treatment decisions. Additionally, it highlights the efficacy and safety profiles of the treatment option.
CA-3326
,